Ponencia

Diagnostic and therapeutic update in narcolepsy

J. Santamaría [REV NEUROL 2012;54 (Supl. 3):S25-S30] PMID: 22605629 DOI: https://doi.org/10.33588/rn.54S03.2012242

OPEN ACCESS

Volumen 54 | Number S03 | Nº of views of the article 7.643 | Nº of PDF downloads 2.068 | Article publication date 21/05/2012

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

Narcolepsy is an emblematic, unique disease within sleep disorders that is characterised by excessive daytime sleepiness, cataplexy and other abnormal manifestations of REM sleep. In the last 14 years truly spectacular progress has been made in our knowledge of this disease, since the discovery of its cause, i.e. a loss of the hypothalamic neurons that synthesise hypocretin, a previously unknown neurotransmitter, and its probable aetiopathogenic mechanisms, i.e. an autoimmune process in a patient with very precise immunological characteristics – a specific type of HLA and a specific type of T-cell receptor. The cause of this autoimmune process remains unknown. The definitive treatment – the administration of hypocretin, which is the substance missing in the organism – is still unavailable, but there are powerful drugs for treating its main symptoms, the sleepiness and the cataplexy. Some of these are classic compounds (methylphenidate, clomipramine), while others are more recent (modafinil, venlafaxine, sodium oxybate), but together they allow many patients to experience significant improvements. Lack of knowledge about the disease, both on the part of patients and their relatives as well as physicians, is the reason for the great delay in its diagnosis, with even more dramatic consequences when the disease begins in infancy. KeywordsCataplexy Hypocretin Immunoglobulins Narcolepsy

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Ponencia

Diagnostic and therapeutic update in narcolepsy